Latest Breaking News On - Subgroup analyses - Page 2 : comparemela.com

Bristol Myers Squibb s First Disclosures and New Data at ASH 2023 Highlight Company s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.

United statesSan diegoSikander ailawadhiFrancesco passamontiLisocabtagene maraleucelGuillaume cartronRavi vijMaroof hasanMark kaplanRachid bazHemophagocytic lymphohistiocytosisDanny jeyarajuSheida hayatiSusan balSamit hirawatFranck morschhauser

Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial | Ophthalmology | JAMA Network Open

This randomized clinical trial assesses the efficacy and safety of a repeated low-level red-light intervention in preventing incident myopia among children in C

Eteläuomen läiXun xuIolmaster carl zeiss meditecXieyi weishikangEyerising ltdNational key rd program of chinaTreatment centerInternational myopia instituteTechnology commissionOutstanding academic technical leaders programEyerising international pty ltdSuzhou xuanjia optoelectronics technologyHospital ethics committeeDepartment of clinical researchChina national medical products administrationInstitute inc

American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & Exposition

American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & Exposition
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew orleansBrentuximab vedotinRalph bocciaGeorge negreaRuemue birhirayRalphv bocciaTodd schonherzVictorm priegoArvind chaudhryEpcoritamab monotherapyAmerican society of hematologySummit cancer centersAmerican oncology networkResearch committeeWall street

Guidelines for Reporting Outcomes in Trial Reports

This report, the Consolidated Standards of Reporting Trials (CONSORT)–Outcomes 2022 extension, is a consensus statement on the standards for reporting outcomes

United statesCity ofUnited kingdomPharma gmbRobin hayeemsJames webbeEli lillyPetros pechlivanoglouLisa stallwoodMss saeedAndrea chiaramidaPeter gilgan centre for researchAmerican college of rheumatologyCundill centre for childAnalysis methods groupHealth sciences

Guidelines for Reporting Outcomes in Trial Protocols

This report, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)–Outcomes 2022 extension, is a consensus statement on the standards

United statesPharma gmbAndrea chiaramidaRobin hayeemsEli lillyPetros pechlivanoglouLisa stallwoodPeter gilgan centre for researchAmerican college of rheumatologyCundill centre for childAnalysis methods groupHealth sciencesForest pharmaceuticalsVertex pharmaceuticalsTakeda pharmaceutical co ltdDrug administration